A recent study has demonstrated that administering miR-519c, which exhibits decreased levels in pancreatic cancer, inhibited HIF1-α within gemcitabine-resistant pancreatic cancer cells under hypoxic conditions [181]. Here, HIF1A is linked to pancreatic neoplasm.